Clinical trial TULIP
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer / TULIP
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Synthon Biopharmaceuticals |
| EudraCT Identifier | 2017-001994-18 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03262935 |
| Inclusion criteria | HER2 positive/ RECIST 1.1/ After HER2 targeting treatment |
| Last update |